Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 5/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.39 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.39 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.39 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.39 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.39 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.39 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921008 | 1.00 | SPHK1 (0.47) | SPHK1SPHK2LTA4HS1PR1S1PR3 | |
| SCHEMBL29307826 | 0.90 | SPHK1 (0.47) | SPHK1SPHK2LTA4HS1PR1S1PR3 | |
| SCHEMBL2670047 | 0.87 | SPHK1 (0.45) | SPHK1SPHK2LTA4HS1PR1S1PR3 | |
| SCHEMBL2670045 | 0.87 | SPHK1 (0.45) | SPHK1SPHK2LTA4HS1PR1S1PR3 | |
| SCHEMBL6290636 | 0.86 | S1PR1 (0.45) | SPHK1SPHK2LTA4HS1PR1S1PR3 | |
| SCHEMBL29308003 | 0.86 | HSD17B10 (0.42) | LTA4HHDAC8ADCY6ADCY3ADCY9 | |
| SCHEMBL23132270 | 0.81 | SPHK1 (0.46) | SPHK1SPHK2LTA4HS1PR1S1PR3 | |
| SCHEMBL20067638 | 0.80 | SPHK1 (0.49) | SPHK1SPHK2LTA4H | |
| SCHEMBL22457856 | 0.80 | SUV39H2 (0.46) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL23125175 | 0.80 | LTA4H (0.62) | SPHK1SPHK2LTA4HS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2025-08-21 | — | — | US | disclosed |
| CN-114728073-B | Selective release of drugs from internalized conjugates of bioactive compounds | 思进股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | JPMORGAN CHASE BANK, N.A. | 2024-07-25 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3900742-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-3900742-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | Seagen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3900742-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | Seagen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3191502-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3191502-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3383420-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seattle Genetics, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2017096311-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | SPHK1 1831/4885SPHK2 1564/4885LTA4H 2192/4885 |
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | SPHK1 1831/4885SPHK2 1564/4885LTA4H 2192/4885 |
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | SPHK1 3264/4885SPHK2 3107/4885LTA4H 1324/4885 |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | SPHK1 3264/4885SPHK2 3107/4885LTA4H 1324/4885 |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | SPHK1 3264/4885SPHK2 3107/4885LTA4H 1324/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | SPHK1 2956/4885SPHK2 2807/4885LTA4H 2924/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | SPHK1 2956/4885SPHK2 2807/4885LTA4H 2924/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | SPHK1 3264/4885SPHK2 3107/4885LTA4H 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.